Precision Biosciences DL !....Zombie oder..

...gentech-Bude mit Potenzial !! mein Kurziel ist = > 20$  bis eoy 2019......  

https://investor.precisionbiosciences.com/...d-quarter-2019-financial

"...announced today that it will publish financial results for the third quarter of 2019 and provide a corporate update on November 12, 2019."

und gleich darauf :

Barclays Gene Editing & Gene Therapy Summit
Nov 13, 2019 at 2:45 PM EST to Nov 13, 2019 at 12:00 AM EST
Add to Outlook
Add to Google Calendar
Location
New York, NY
Speaker: Matt Kane, Chief Executive Officer

MfG  

https://seekingalpha.com/pr/...9-financial-results-highlights-ongoing  

https://seekingalpha.com/pr/...expert-kevin-j-buehler-board-directors  

..noch knapp 0.50$ bevor die nächste stufe ab 10$ zündet.

gn8

MfG  

 

wäre ja schon zufrieden wenn der SK das niveau halten könnte........  

abläuft.......es muß wohl positiv sein.


DTIL   $10.145*0.675   7.12%

*Real-Time - data as of 11/14/2019 10:48:16 AM  

"Mr. Buehler has over thirty years of experience in the healthcare industry. He spent the majority of his career with Alcon Laboratories, a publicly traded ophthalmology-focused healthcare company headquartered in Fort Worth, Texas. At Alcon, Mr. Buehler rose through the commercial organization, eventually becoming CEO, leading the company?s sale to Novartis and subsequently serving as Alcon division head within Novartis. He will assume the chairmanship of Precision?s Nominating and Corporate Governance Committee (replacing Mr. Kane), and will also join the company?s Audit Committee (replacing Dr. Adelman)."

ok so kommt auch noch Phantasie mit rein.......

MFG  

https://www.fool.com/investing/2019/11/14/...es-is-soaring-today.aspx

MfG  

 

 

CRSP  Market Cap 2.94B  CRISPR Therapeutics AG
DTIL   Market Cap 453.90M   Precision BioSciences, Inc.
NTLA  Market Cap 669.96M  Intellia Therapeutics, Inc.
EDIT  Market Cap 1.16B  Editas Medicine, Inc.
SRPT  Market Cap 7.28B   Sarepta Therapeutics, Inc.

Da ist in der Tat noch viel Potenzial nach oben !!

MfG  

unaufhaltsam auf die 12$ zu....

MfG  

ist hier die nächste Rakete am Start........

MfG  

PRECISION BIOSCIENCES DL
          §11,95 ? +8,14%

bin mal auf Schlusskurs gespannt.

MfG  

PRECISION BIOSCIENCES DL
          §12,35 ? +11,76%

nächste Woche gehts dann weiter.

MfG  

völlig unterbewertet das Teil.

MfG  

 

https://www.biopharmcatalyst.com/calendars/fda-calendar

MfG  

 

"As of late, it has definitely been a great time to be an investor inPrecision BioSciences, Inc. DTIL. The stock has moved higher by more than 100% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path."

https://finance.yahoo.com/news/...f_Hh6aIw7270uToMGNf9fHZadrmq02iZT9y

MfG  ohh 17$ gerade durch...  

lasst den anderen doch auch noch ein paar Stücke übrig. ..

Precision BioSciences, Inc. Common Stock Real Time Stock Quotes
DTIL
$17.75*1.59  9.83%
*Real-Time - data as of 11/27/2019 2:10:33 PM -  Find a broker to begin trading DTIL now

Schönen Gruß
 

mit der Schlussglocke :
 

...und uns Shareholder.

https://investor.precisionbiosciences.com/events/event-details/american-society-hematology-ash-annual-meeting-clinical-data-presentation

"....The abstract outlining initial data from patients treated with PBCAR0191 at Dose Level 1 can be accessed on the ASH conference website. Data in the abstract include results as of the cutoff date of August 1, 2019 for three patients with advanced NHL treated at Dose Level 1. No significant toxicities were observed, including no serious adverse events and no dose-limiting toxicities. All patients had a minimum follow-up of 28 days (median 60 days). Two of the three patients experienced an objective tumor response by Lugano criteria, at day 14 and day 28, respectively. The third patient, who had previously progressed following treatment with axicabtagene ciloleucel (Yescarta®), an approved anti-CD19 autologous CAR T therapy, had not met the definition of response, but demonstrated evidence of central necrosis, decreased tumor size, and decreased PET-avidity at day 28, in the context of post-infusion tumor site pain and mild CRS symptoms. Peripheral blood analysis for CAR T cell expansion has identified preliminary evidence of cell expansion."

Ich bin eigentlich guter Dinge, habe aber auch schon oft daneben gelegen.

Viele Mitstreiter schein es ja hier nicht zu geben.

MfG

 

Ich nehme die Kursentwicklung mal wohlwollend zur Kentniss...